Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
Xiaofeng ChenXiaofeng WuHao WuYanhong GuYang ShaoQianwen ShaoFeipeng ZhuXiao LiXiaofeng QianJun HuFengjiao ZhaoWeidong MaoJing SunJian WangGaohua HanChangxian LiYongxiang XiaPoshita Kumari SeesahaDongqin ZhuHuajun LiJunling ZhangGuoqiang WangXuehao WangXiangcheng LiYongqian ShuPublished in: Journal for immunotherapy of cancer (2021)
NCT03486678.